|
May 15
|
Taysha Gene Therapies Inc (TSHA) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
|
|
May 14
|
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 14
|
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 7
|
Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14
|
|
May 2
|
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know
|
|
May 2
|
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
|
|
Apr 29
|
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
|
|
Apr 20
|
Analysts' Revenue Estimates For Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Are Surging Higher
|
|
Apr 15
|
Certain Biotech Investors Get an Early Look at Results. Is That Fair?
|
|
Apr 5
|
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 24
|
News Flash: Analysts Just Made A Notable Upgrade To Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Forecasts
|
|
Mar 21
|
Taysha Gene Therapies Full Year 2023 Earnings: Beats Expectations
|
|
Mar 20
|
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2023 Earnings Call Transcript
|
|
Mar 20
|
Q4 2023 Taysha Gene Therapies Inc Earnings Call
|
|
Mar 19
|
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
|
|
Mar 14
|
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
|
|
Jan 15
|
3 Growth Stocks That Could Go Parabolic in 2024
|
|
Jan 10
|
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
|
|
Dec 19
|
Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies
|
|
Nov 29
|
Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients
|